What the FDA labels say about taking them together
Disopyramide and insulin human
Insulin human's FDA label of March 7, 2025 names disopyramide in its drug interactions section; the disopyramide label PlainMeds reads does not name insulin human. The insulin human label: “Clinically Significant Drug Interactions with AFREZZA Antidiabetic agents, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blocking Agents, Disopyramide, Fibrates, Fluoxetine, Monoamine Oxidase …”
Check it at the source: the disopyramide FDA label on DailyMed (effective August 24, 2026, Pfizer Laboratories Div Pfizer Inc); the insulin human FDA label on DailyMed (effective March 7, 2025, Baxter Healthcare Corporation).
What does the disopyramide label say about insulin human?
Disopyramide's label (effective August 24, 2026) does not name insulin human in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Norpace), Pfizer Laboratories Div Pfizer Inc, effective August 24, 2026 (SPL set e2aa1642-d262-4520-bc6a-9fd3ad795677), via openFDA; the full label on DailyMed
What does the insulin human label say about disopyramide?
Insulin human label, drug interactionsDrugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when MYXREDLIN is co-administered with these drugs.
Afrezza label (Mannkind Corporation, May 30, 2026), drug interactionsClinically Significant Drug Interactions with AFREZZA Antidiabetic agents, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blocking Agents, Disopyramide, Fibrates, Fluoxetine, Monoamine Oxidase Inhibitors, Pentoxifylline, Pramlintide, Salicylates, Somatostatin Analogs (e.g., octreotide), and Sulfonamide Antibiotics Prevention or Management Monitor blood glucose more frequently and modify AFREZZA dosage, as clinically indicated, when used concomitantly with these drugs.
Source: FDA drug label (Afrezza, BLA022472), Mannkind Corporation, effective May 30, 2026 (SPL set 29f4637b-e204-425b-b89c-7238008d8c10), via openFDA
Source: FDA drug label (MYXREDLIN), Baxter Healthcare Corporation, effective March 7, 2025 (SPL set afca6e80-a802-49fb-a978-5fe28a173001), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Disopyramide | Insulin human | |
|---|---|---|
| Labeled for | n/a | Type 2 diabetes, Type 1 diabetes |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.801 per capsule 100 mg capsule | $4.26 per mL 70-30 vial |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once